Coya Therapeutics, Inc. carries no debt; cash flow comfortably covers obligations.

Coya Therapeutics, Inc.'s free cash flow has decreased 4.38% from $-10.29M last year to $-10.74M, signaling decreasing performance

Coya Therapeutics, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Coya Therapeutics, Inc. has insufficient data to evaluate this check.

Coya Therapeutics, Inc. has a net cash position, so leverage is healthy.

Coya Therapeutics, Inc. carries no debt; interest obligations are fully covered.

Coya Therapeutics, Inc.'s profit margin has decreased (531.77%) in the last year from -418.70% to -2.65K%, signaling decreasing performance

Coya Therapeutics, Inc.'s short-term assets of $49.94M exceed its short-term liabilities of $5.87M

Coya Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Coya Therapeutics, Inc.'s return on equity of -61.33%, is lower than 15.00%, indicating bad performance

Coya Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Coya Therapeutics, Inc. has insufficient public price history to evaluate earnings stability.

Coya Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Coya Therapeutics, Inc. has negative free cash flow, indicating cash burn

Coya Therapeutics, Inc.'s yearly earnings has decreased 42.64% since last year from $-14.88M to $-21.23M, signaling decreasing performance

Coya Therapeutics, Inc.'s yearly revenue has increased 123.57% since last year from $3.55M to $7.95M, signaling increasing performance

ROIC -16.13% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Coya Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Coya Therapeutics, Inc. has insufficient public price history to evaluate revenue consistency.

Coya Therapeutics, Inc. has insufficient public price history to evaluate ROE consistency.

Coya Therapeutics, Inc. is overvalued relative to its fair value price of 2.07 based on Discounted Cash Flow model

Coya Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Coya Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Coya Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Coya Therapeutics, Inc. has insufficient data to evaluate this check.

Coya Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Coya Therapeutics, Inc. has a price-to-book ratio of 0.00x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Coya Therapeutics, Inc. has a price-to-sales ratio of 0.43x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue